Stem Cell Sciences Plc (SCS) is closing its office in Edinburgh, UK, streamlining its operations in Melbourne, Australia, and moving its operational base to the Babraham Research Campus in Cambridge, UK, where management will focus on negotiating research collaborations with pharmaceutical companies.
Pronova BioPharma ASA, which produces marine-originated pharmaceutical products, said revenues increased by 32.3% in the fourth quarter of 2007 to NOK 269.4 million on stronger US sales of its lead product, Lovaza.
Scientists at the University of Oxford’s Jenner Institute have started a Phase 1 trial for a new candidate vaccine against malaria, which is designed to stimulate an immune response to the malaria parasite by using a genetically modified chimpanzee adenovirus.
The number of companies seeking SME status (Small and Medium-sized Enterprise) with the European Medicines Agency rose by 40% in 2007 from a year earlier, according to Melanie Carr, head of the agency’s SME office.
Newron Pharmaceuticals SpA, the Italian biopharmaceutical company, is to acquire Hunter-Fleming Ltd., a privately-held British company focused on neurodegenerative and inflammatory disorders, in an all-share transaction.
Small and medium-sized companies (SMEs) that have done preclinical work on developing advanced therapies, such as gene or cell products, will be eligible to receive a certificate from the European Medicines Agency (EMEA) verifying that their preclinical data package meets European regulatory standards for quality and safety.
4SC AG, which has developed a computer-based technology for screening drug candidates, has entered into a research collaboration with the Wuppertal-based company, AiCuris GmbH, to investigate anti-infective drug candidates.
CeNeS Pharmaceuticals Plc said it is in discussions which may or may not lead to an offer for the company.
GE Healthcare, the medical diagnostics unit of General Electric Co. of the US, has made a cash offer for all the shares of Whatman Plc, a British supplier of filters and membranes for laboratory research.
A committee of the House of Commons has raised questions about the Labour government’s commitment to a proposed new medical centre for central London following the disclosure that the Treasury has clawed back £92 million from savings accumulated by the Medical Research Council for financing the project.